Datapoint: Novartis Scores Full Approval for Tabrecta

The FDA last week granted regular approval to Novartis Pharmaceuticals Corp.’s Tabrecta for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have the mesenchymal-epithelial transition (MET) gene, a rare mutation found in about 4% of patients. The kinase inhibitor received accelerated approval in May 2020, based on positive clinical trial data. For the treatment of NSCLC, Tabrecta currently holds covered or better status for 93% of all insured lives under the pharmacy benefit. About 25% of insured lives have preferred access to Tabrecta.

SOURCE: MMIT Analytics, as of 8/17/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today